DE69534601D1 - Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien - Google Patents
Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterienInfo
- Publication number
- DE69534601D1 DE69534601D1 DE69534601T DE69534601T DE69534601D1 DE 69534601 D1 DE69534601 D1 DE 69534601D1 DE 69534601 T DE69534601 T DE 69534601T DE 69534601 T DE69534601 T DE 69534601T DE 69534601 D1 DE69534601 D1 DE 69534601D1
- Authority
- DE
- Germany
- Prior art keywords
- bacteria
- myko
- grampositive
- antibodies
- effects caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30793194A | 1994-09-16 | 1994-09-16 | |
US307931 | 1994-09-16 | ||
PCT/US1995/011770 WO1996008272A1 (en) | 1994-09-16 | 1995-09-15 | Use of antibodies to block the effects of gram-positive bacteria and mycobacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69534601D1 true DE69534601D1 (de) | 2005-12-15 |
DE69534601T2 DE69534601T2 (de) | 2006-08-03 |
Family
ID=23191790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69534601T Expired - Lifetime DE69534601T2 (de) | 1994-09-16 | 1995-09-15 | Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien |
Country Status (9)
Country | Link |
---|---|
US (3) | US6168790B1 (de) |
EP (1) | EP0792162B1 (de) |
JP (1) | JP3892902B2 (de) |
AT (1) | ATE308994T1 (de) |
CA (1) | CA2200054C (de) |
DE (1) | DE69534601T2 (de) |
DK (1) | DK0792162T3 (de) |
ES (1) | ES2255708T3 (de) |
WO (1) | WO1996008272A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766593A (en) * | 1994-12-30 | 1998-06-16 | Amgen Inc. | Anti-inflammatory CD14 peptides |
WO1997000081A1 (en) * | 1995-06-19 | 1997-01-03 | Goyert Sanna M | A method for inhibiting bacteremia and bacterial dissemination |
US6610293B1 (en) * | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
WO2000042994A2 (en) * | 1999-01-21 | 2000-07-27 | North Shore-Long Island Jewish Research Institute | Inhibition of bacterial dissemination |
US6916628B1 (en) | 1999-09-17 | 2005-07-12 | Mochida Pharmaceutical Co., Ltd. | Method for the measurement of soluble CD14 proteins separately |
WO2001072993A1 (fr) * | 2000-03-31 | 2001-10-04 | Mochida Pharmaceutical Co., Ltd. | Inhibiteur de liaison entre le recepteur de type toll et cd14 |
US7264967B2 (en) | 2000-11-22 | 2007-09-04 | Mochida Pharmaceutical Co., Ltd. | Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding |
US20040028651A1 (en) * | 2001-03-29 | 2004-02-12 | Karrupiah Muthumani | Composition and methods of using hiv vpr |
CN1564696A (zh) * | 2001-10-05 | 2005-01-12 | 宾西法尼亚大学托管人 | 治疗和预防全身炎性反应综合症/败血症的药物组成和方法 |
EP1628530B8 (de) * | 2003-05-15 | 2012-08-01 | Genentech, Inc. | Verfahren und zubereitungen zur vorbeugung und behandlung von sepsis |
WO2012102679A1 (en) | 2011-01-24 | 2012-08-02 | National University Of Singapore | Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins |
KR20200015477A (ko) * | 2017-04-21 | 2020-02-12 | 임플리싯 바이오사이언스 피티와이 엘티디 | 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU645515B2 (en) * | 1989-08-01 | 1994-01-20 | Rockefeller University, The | Methods and compositions for ameliorating the symptoms of sepsis |
CA2075298A1 (en) * | 1990-02-01 | 1991-08-02 | Samuel D. Wright | Lipopolysaccharide binding opsonin and methods of use thereof |
WO1994028025A1 (en) * | 1993-05-28 | 1994-12-08 | The Scripps Research Institute | Methods and compositions for inhibiting cd14 mediated cell activation |
-
1995
- 1995-09-15 DE DE69534601T patent/DE69534601T2/de not_active Expired - Lifetime
- 1995-09-15 WO PCT/US1995/011770 patent/WO1996008272A1/en active IP Right Grant
- 1995-09-15 CA CA2200054A patent/CA2200054C/en not_active Expired - Fee Related
- 1995-09-15 DK DK95933826T patent/DK0792162T3/da active
- 1995-09-15 ES ES95933826T patent/ES2255708T3/es not_active Expired - Lifetime
- 1995-09-15 JP JP51038296A patent/JP3892902B2/ja not_active Expired - Fee Related
- 1995-09-15 EP EP95933826A patent/EP0792162B1/de not_active Expired - Lifetime
- 1995-09-15 AT AT95933826T patent/ATE308994T1/de not_active IP Right Cessation
-
1998
- 1998-06-19 US US09/099,957 patent/US6168790B1/en not_active Expired - Lifetime
-
2000
- 2000-12-19 US US09/742,599 patent/US20010022969A1/en not_active Abandoned
-
2002
- 2002-07-25 US US10/206,382 patent/US20030103969A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPH10505839A (ja) | 1998-06-09 |
DE69534601T2 (de) | 2006-08-03 |
ES2255708T3 (es) | 2006-07-01 |
US6168790B1 (en) | 2001-01-02 |
JP3892902B2 (ja) | 2007-03-14 |
CA2200054A1 (en) | 1996-03-21 |
AU703169B2 (en) | 1999-03-18 |
EP0792162B1 (de) | 2005-11-09 |
EP0792162A4 (de) | 2003-03-19 |
CA2200054C (en) | 2010-03-16 |
US20010022969A1 (en) | 2001-09-20 |
US20030103969A1 (en) | 2003-06-05 |
DK0792162T3 (da) | 2006-03-27 |
ATE308994T1 (de) | 2005-11-15 |
EP0792162A1 (de) | 1997-09-03 |
AU3633695A (en) | 1996-03-29 |
WO1996008272A1 (en) | 1996-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI920450A0 (fi) | Metoder och kompositioner foer foerhindrande av symtomer av sepsis. | |
DE69534601D1 (de) | Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien | |
ATE448792T1 (de) | Verwendung von botulinumtoxin zur behandlung der renitenten blasenentleerungsstörung | |
DE69129989D1 (de) | Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore | |
ATE215832T1 (de) | Botulinumtoxin zur reduktion von migraine - kopfschmerzen | |
DE69321909D1 (de) | Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden | |
PT751781E (pt) | Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas | |
ATE248605T1 (de) | Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper | |
RU2000105905A (ru) | Способ лечения острого повреждения легких и способ лечения фиброза, моноклональное антитело, гибридома атсс нв12382 | |
FI964845A0 (fi) | CD44v6:n vastaiset monoklonaaliset vasta-aineet | |
SE8605295D0 (sv) | Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes | |
ATA29495A (de) | Zusammensetzung und verfahren zur prävention und behandlung von entzündungen mit immunglobulin a | |
DE69434384D1 (de) | Metalkomplexbildner | |
ATE410514T1 (de) | Calciumbindende rekombinante antikörper gegen protein c | |
DK1042492T3 (da) | Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme | |
DE69327248D1 (de) | Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium | |
ATE136222T1 (de) | Heilmittel und verfahren zur inhibierung der vaskularisierung von tumoren | |
DK0583281T3 (da) | Modgift - immunsera | |
Moroz et al. | Neutralization of Vipera palestinae hemorrhagin by antibody fragments | |
ATE157121T1 (de) | Behandlung thrombotischer ereignisse | |
FI924278A0 (fi) | Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |